Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
暂无分享,去创建一个
B. Mellado | J. Albanell | P. Gascón | A. Rovira | Pere Gascón | Joan Albanell | Ana Rovira | J. Codony | Jordi Codony | Begoña Mellado
[1] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[2] M. Eisenstein,et al. Bivalence of EGF‐like ligands drives the ErbB signaling network , 1997, The EMBO journal.
[3] C. Arteaga,et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. , 2002, Cancer research.
[4] Y. Yarden,et al. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. , 2000, Cancer research.
[5] M. Sliwkowski,et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.
[6] Robert A. Weinberg,et al. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.
[7] J. Garcia-conde,et al. NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer , 2002 .
[8] W. Dougall,et al. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[9] Brian Higgins,et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.
[10] P. Carter,et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies , 1993, Cancer Immunology, Immunotherapy.
[11] Yosef Yarden,et al. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.
[12] Jun Yao,et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. , 1998, Molecular cell.
[13] C. Benz,et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] T. Fleming,et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial , 1998 .
[15] A. Ullrich,et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.
[16] R. Bianco,et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.
[17] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Y. Lu,et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.
[19] R. Schwall,et al. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. , 2002, Cancer research.
[20] A. Lenferink,et al. Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.
[21] Yosef Yarden,et al. ErbB Receptors and EGF-like Ligands: Cell Lineage Determination and Oncogenesis Through Combinatorial Signaling , 1997, Journal of Mammary Gland Biology and Neoplasia.
[22] E. Winer,et al. Trastuzumab/chemotherapy combinations in metastatic breast cancer. , 2002, Seminars in oncology.
[23] J. Doherty,et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. , 1998, Cancer research.
[24] J. Baselga,et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. , 2001, Cancer research.
[25] N. Goldstein,et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.
[26] J. Baselga,et al. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. , 1999, Cancer research.
[27] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[28] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[29] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.
[30] M. Sliwkowski,et al. Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects , 2004, Cancer Research.
[31] A. Ribas,et al. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. , 1996, Anticancer research.
[32] M. Sliwkowski,et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.
[33] J. Mendelsohn,et al. Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225 , 1999, Oncogene.
[34] J. Slingerland,et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.
[35] J. Baselga,et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.
[36] J. Schlessinger,et al. Regulation of signal transduction and signal diversity by receptor oligomerization. , 1994, Trends in biochemical sciences.
[37] J. Baselga,et al. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. , 2001, Journal of the National Cancer Institute.
[38] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[39] Z. Fishelson,et al. Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. , 1999, Immunopharmacology.
[40] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[41] Yosef Yarden,et al. Biology of HER2 and Its Importance in Breast Cancer , 2001, Oncology.
[42] Makoto Katsumata,et al. Prevention of breast tumour development in vivo by downregulation of the p185neureceptor , 1995, Nature Medicine.
[43] Y. Yarden,et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.
[44] I. Ellis,et al. Phosphorylation of ERK1/2 mitogen‐activated protein kinase is associated with poor response to anti‐hormonal therapy and decreased patient survival in clinical breast cancer , 2001, International journal of cancer.
[45] M. Kraus,et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.
[46] M. Sliwkowski,et al. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. , 2001, Cancer research.
[47] G. Carpenter,et al. All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.
[48] A. Harris,et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] L. Presta,et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[50] A. Ullrich,et al. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[51] Carlos L. Arteaga,et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.
[52] G. Carpenter,et al. Selective Cleavage of the Heregulin Receptor ErbB-4 by Protein Kinase C Activation* , 1996, The Journal of Biological Chemistry.
[53] N. Rosen,et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.
[54] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[55] John M. Daly,et al. ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.
[56] M. Sliwkowski,et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.
[57] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] Lei Xu,et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.
[59] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[60] J. Baselga,et al. Mechanism of action of trastuzumab and scientific update. , 2001, Seminars in oncology.
[61] Alfonso Bellacosa,et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer , 2002, Nature Medicine.
[62] Y. Yarden,et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.
[63] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[64] J. Baselga,et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] Y. Yarden,et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[66] G. Hortobagyi,et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. , 2002, Cancer research.